Drug Profile


Alternative Names: ALKS-37; RDC-1036

Latest Information Update: 22 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rensselaer Polytechnic Institute
  • Developer Alkermes plc
  • Class Amides; Morphine derivatives; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Constipation

Most Recent Events

  • 30 Jun 2012 Alkermes completes a phase IIb trial for Opioid-induced constipation in USA (NCT01418092)
  • 30 May 2012 Discontinued - Phase-II for Opioid-induced constipation in USA (PO)
  • 13 Mar 2012 Alkermes completes enrolment in its phase IIb trials for Opioid-induced constipation in USA (NCT01382797; NCT01418092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top